Want to see IN:KOPRAN full AI Analyst Report?
Top Page
Kopran Limited
(KOPRAN)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹250.00
▲(64.26% Upside)
Action:Reiterated
Date:08/26/26
The score is primarily held back by weak cash-flow quality, with persistently negative free cash flow despite decent revenue growth and a moderate-leverage balance sheet. Technicals are mildly supportive with price above key moving averages and neutral momentum. Valuation remains a drag due to a high P/E, only partially offset by a modest dividend yield.
Positive Factors
Revenue Growth
Revenue growth has remained solid and accelerated to about 15% in FY2026 after modest FY2025 growth. This indicates continued demand across the portfolio and can support operating scale, reinvestment, and stronger market presence if the trajectory persists.
Negative Factors
Persistently Negative Free Cash Flow
Persistent negative free cash flow indicates that operating cash has not covered investment or working-capital needs. If sustained, this weakens financial flexibility, limits internally funded growth, and may increase reliance on external funding despite positive operating cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue growth has remained solid and accelerated to about 15% in FY2026 after modest FY2025 growth. This indicates continued demand across the portfolio and can support operating scale, reinvestment, and stronger market presence if the trajectory persists.
Read all positive factors
Kopran Limited (KOPRAN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹11.24B
Dividend Yield1.22%
Average Volume (3M)21.00K
Price to Earnings (P/E)45.1
Beta (1Y)1.42
Revenue Growth11.96%
EPS Growth-28.48%
CountryIN
Employees1,156
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)5.17
Shares Outstanding48,285,606
10 Day Avg. Volume41,981
30 Day Avg. Volume21,001
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)0.98
Price to Sales (P/S)0.77
P/FCF Ratio-49.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kopran Limited Business Overview & Revenue Model
Company Description
Kopran Limited is a fully integrated pharmaceutical entity that manufactures and distributes both active pharmaceutical ingredients (APIs) and finished drug products, serving markets in India and worldwide. Its extensive product portfolio includes...
How the Company Makes Money
Kopran Limited primarily makes money by selling (1) finished pharmaceutical formulations (branded and/or generic medicines in dosage forms such as tablets, capsules, syrups, etc.) and (2) active pharmaceutical ingredients (APIs) supplied to other ...
Kopran Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
70
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.00B | 6.81B | 6.30B | 6.15B | 5.48B | 4.74B |
| Gross Profit | 1.89B | 1.60B | 2.25B | 2.09B | 1.86B | 1.90B |
| EBITDA | 614.17M | 623.00M | 729.00M | 868.18M | 548.77M | 980.11M |
| Net Income | 249.83M | 257.31M | 385.52M | 509.56M | 272.33M | 610.31M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 9.08B | 8.44B | 7.43B | 6.50B | 6.11B |
| Cash, Cash Equivalents and Short-Term Investments | 6.82M | 72.22M | 258.64M | 80.91M | 73.97M | 58.68M |
| Total Debt | 0.00 | 1.53B | 1.48B | 992.28M | 752.38M | 745.49M |
| Total Liabilities | -5.30B | 3.78B | 3.26B | 2.52B | 2.10B | 1.85B |
| Stockholders Equity | 5.30B | 5.30B | 5.18B | 4.91B | 4.39B | 4.26B |
Cash Flow | ||||||
| Free Cash Flow | 234.30M | -105.46M | -134.46M | -133.56M | -270.22M | -757.47M |
| Operating Cash Flow | 553.87M | 565.79M | 419.42M | 432.58M | 340.23M | -334.75M |
| Investing Cash Flow | -335.65M | -648.97M | -564.28M | -435.52M | -126.50M | -844.15M |
| Financing Cash Flow | -107.78M | -104.72M | 258.68M | 9.88M | -198.44M | 1.23B |
Kopran Limited Technical Analysis
Positive
152.20
Price Trends
195.92
Positive
183.62
Positive
157.79
Positive
Market Momentum
11.36
Negative
78.62
Negative
85.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KOPRAN, the sentiment is Positive. The current price of 152.2 is below the 20-day moving average (MA) of 202.88, below the 50-day MA of 195.92, and below the 200-day MA of 157.79, indicating a bullish trend. The MACD of 11.36 indicates Negative momentum. The RSI at 78.62 is Negative, neither overbought nor oversold. The STOCH value of 85.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KOPRAN.
Kopran Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ₹147.94B | 28.73 | ― | 0.27% | 19.59% | 47.58% | |
79 Outperform | ₹1.12T | 33.18 | ― | 2.08% | 1.85% | -37.51% | |
71 Outperform | ₹72.54B | 22.43 | ― | 3.94% | -8.88% | -10.68% | |
70 Outperform | ₹17.95B | 31.32 | ― | 0.06% | 40.45% | 174.03% | |
63 Neutral | ₹36.78B | 35.05 | ― | 0.10% | 10.25% | 33.78% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₹11.24B | 45.07 | ― | 1.22% | 11.96% | -28.48% |
* General Sector Average
IN:KOPRAN
Kopran Limited
240.20
58.73
32.36%
IN:CIPLA
Cipla Ltd
1,383.95
-153.47
-9.98%
IN:MARKSANS
Marksans Pharma Limited
335.90
164.32
95.77%
IN:NGLFINE
NGL Fine-Chem Ltd.
2,802.75
1,377.10
96.59%
IN:SANOFI
Sanofi India Limited
3,116.15
-1,787.67
-36.45%
IN:SMSPHARMA
SMS Pharmaceuticals Limited
398.95
150.34
60.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.